A Q&A with Uwe Ross of Binder - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Q&A with Uwe Ross of Binder
The president of Binder, a manufacturer of simulation chambers, addresses the consolidation of Big Pharma, and more.

Pharmaceutical Technology
Volume 6, Issue 34, pp. 62


Uwe Ross
PharmTech:
What is the biggest industry challenge you're now facing?

Ross:
The consolidation of Big Pharma will continue as the US Food and Drug Administration approves fewer blockbuster drugs and as the existing patents on the money-making drugs expire. These developments are taking a big portion of private-sector research money out of the market. Research funds will shift toward other companies and institutes such as small biopharmaceutical firms and universities, and we must focus on serving these companies, too.

PharmTech:
How do you stay abreast of new developments in the industry?

Ross:
Just do three things and do them well: listen to the customer, listen to the customer, and listen to the customer.

PharmTech:
Do you see a new industry trend emerging?

Ross:
Americans and their government are trying to lower their heathcare costs. The average person living in the US currently spends more than $1000 per year on pharmaceuticals. Most of this money is spent on chronic diseases, but the treatments often are ineffective and a good portion of the money thus is wasted. Our method of marketing a blockbuster drug as "one cure for all" is not working and is too expensive. We will see a shift toward personalized treatment and preventive measures which will be more effective than blockbusters, as well as cost-effective, not too far in the future. The age of Big Pharma will shift to the age of biotech!

PharmTech:
What is the most common demand your clients are currently making of you?

Ross:
Our clients are more and more pressed for time. In the past, the end user had time to research and find the best product for his or her application. The responsibility for this research has shifted to the manufacturer today. The customer expects us to understand their application and needs and to offer the best, most cost-effective product for the lifetime of the application.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
43%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here